新冠疫苗在免疫功能低下成人中预防急诊或紧急护理就诊及住院的有效性:基于美国10州2021年8月至12月真实世界数据的观察性研究
该研究采用检测阴性设计,比较免疫功能低下(IC)与非免疫功能低下(非IC)成人接种2-3剂mRNA或1-2剂病毒载体疫苗后对COVID-19相关急诊/紧急护理及住院的疫苗有效性(VE)。在Delta变异株流行期间,IC成人接种3剂mRNA疫苗对急诊/紧急护理的VE为73%(95%CI:64-80),对住院的VE为81%(95%CI:76-86),均低于非IC成人(分别为94%和96%);移植受者VE更低。
要点
- IC成人3剂mRNA疫苗对急诊/紧急护理VE为73%,对住院VE为81%,低于非IC成人的94%和96%。
- 病毒载体疫苗也呈现类似模式。
- 移植受者的VE低于其他IC亚组。
核心结论
- 在B.1.617.2(Delta)变异株流行期间,IC成人接种3剂mRNA疫苗或1剂病毒载体疫苗加任何产品的第二剂后,对COVID-19相关医疗事件获得中等保护。
- IC患者的保护低于非IC患者,尤其是移植受者,强调IC成人需要额外保护。
研究设计与样本
- 采用检测阴性设计的观察性研究,基于八个VISION网络站点,纳入IC和非IC成人,评估2021年8月26日至12月25日期间实验室确诊COVID-19相关急诊(ED)或紧急护理(UC)事件及住院的VE。
- 分析纳入IC患者8,848例ED/UC事件和18,843例住院,非IC患者200,071例ED/UC事件和70,882例住院。
- 疫苗接种状态根据剂次数量和时间定义,VE针对每种状态(对比未接种)调整年龄、地理、时间、既往阳性检测结果和局部SARS-CoV-2流行。
主要发现
- IC患者3剂mRNA疫苗对ED/UC的VE为73%(95%CI:64-80),对住院的VE为81%(95%CI:76-86)。
- 非IC患者3剂mRNA疫苗对ED/UC的VE为94%(95%CI:93-94),对住院的VE为96%(95%CI:95-97)。
- 病毒载体疫苗也观察到类似模式。
- 移植受者的VE低于其他IC亚组。
关键数值与推荐
- IC患者3剂mRNA疫苗对ED/UC的VE为73%(95%CI:64-80),对住院的VE为81%(95%CI:76-86)。
- 非IC患者3剂mRNA疫苗对ED/UC的VE为94%(95%CI:93-94),对住院的VE为96%(95%CI:95-97)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunocompromised (IC) persons are at increased risk for severe COVID-19 outcomes and are less protected by 1-2 COVID-19 vaccine doses than are immunocompetent (non-IC) persons. We compared vaccine effectiveness (VE) against medically attended COVID-19 of 2-3 mRNA and 1-2 viral-vector vaccine doses between IC and non-IC adults. METHODS: Using a test-negative design among eight VISION Network sites, VE against laboratory-confirmed COVID-19-associated emergency department (ED) or urgent care (UC) events and hospitalizations from 26 August-25 December 2021 was estimated separately among IC and non-IC adults and among specific IC condition subgroups. Vaccination status was defined using number and timing of doses. VE for each status (versus unvaccinated) was adjusted for age, geography, time, prior positive test result, and local SARS-CoV-2 circulation. RESULTS: We analyzed 8,848 ED/UC events and 18,843 hospitalizations among IC patients and 200,071 ED/UC events and 70,882 hospitalizations among non-IC patients. Among IC patients, 3-dose mRNA VE against ED/UC (73% [95% CI: 64-80]) and hospitalization (81% [95% CI: 76-86]) was lower than that among non-IC patients (ED/UC: 94% [95% CI: 93-94]; hospitalization: 96% [95% CI: 95-97]). Similar patterns were observed for viral-vector vaccines. Transplant recipients had lower VE than other IC subgroups. CONCLUSIONS: During B.1.617.2 (Delta) variant predominance, IC adults received moderate protection against COVID-19-associated medical events from three mRNA doses, or one viral-vector dose plus a second dose of any product. However, protection was lower in IC versus non-IC patients, especially among transplant recipients, underscoring the need for additional protection among IC adults.
引用
- Embi PJ, Levy ME, Patel P, et al. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023. PMID: 37479609. doi:10.1016/j.vaccine.2023.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。